Form 4: Replimune CMO Granted 60,000 Restricted Stock Units

Replimune Group's Chief Medical Officer, Konstantinos Xynos, was granted 60,000 restricted stock units, vesting over two years.

Summary

• Konstantinos Xynos, Chief Medical Officer of Replimune Group, Inc. (REPL), was granted 60,000 shares of the Issuer's common stock in the form of Restricted Stock Units (RSUs).
• The transaction date for this acquisition was December 19, 2025.
• The acquisition price for these RSUs was $0, as is typical for such grants.
• Following this transaction, Konstantinos Xynos beneficially owns 199,685 shares of common stock.
• The RSUs will vest in two equal tranches: 50% on November 15, 2026, and the remaining 50% on November 15, 2027.
• Vesting is contingent upon Konstantinos Xynos' continuous service to Replimune Group, Inc.

Sentiment

Score: 7

Explanation: The RSU grant is a positive signal for executive retention and alignment of interests, reflecting standard compensation practices without indicating any negative operational or financial issues.

Positives

• The RSU grant aligns the Chief Medical Officer's long-term interests with those of shareholders, incentivizing sustained performance and company growth.
• This compensation structure serves as a retention mechanism, encouraging the executive to remain with the company through the vesting periods.

Negatives

• The future vesting of these RSUs will result in a minor dilution of existing shareholder equity, though this is a standard component of executive compensation.

Risks

• The vesting of the granted RSUs is subject to the Reporting Person's continuous service to Replimune Group, Inc., meaning the shares are not guaranteed if employment ceases before vesting dates.

Future Outlook

The RSU grant indicates a continued commitment from the Chief Medical Officer to Replimune Group, Inc., with vesting scheduled through November 2027, contingent on continuous service.

Industry Context

The grant of Restricted Stock Units to a Chief Medical Officer is a common practice in the biotechnology and pharmaceutical industry for executive compensation, aiming to attract, retain, and incentivize key talent by linking their compensation to the company's long-term stock performance.

Comparison to Industry Standards

• The RSU grant to a senior executive like a Chief Medical Officer is a standard compensation mechanism widely adopted across the biotech and pharmaceutical sectors, comparable to practices at companies like Moderna, BioNTech, or Gilead Sciences, which frequently use equity awards to align executive interests with shareholder value.
• The vesting schedule, split over two years, is also typical for such grants, providing a balance between immediate incentive and long-term retention, similar to equity compensation plans observed at peer companies.

Stakeholder Impact

• Shareholders: Minor potential future dilution upon vesting, but increased alignment of executive interests with long-term shareholder value.
• Employees: Reinforces the company's commitment to competitive executive compensation, potentially influencing overall compensation strategies.

Next Steps

• First tranche of 30,000 RSUs to vest on November 15, 2026, subject to continuous service.
• Second tranche of 30,000 RSUs to vest on November 15, 2027, subject to continuous service.

Key Dates

Recommendation

This Form 4 reports a routine executive compensation event (RSU grant) and does not contain information that would fundamentally alter the investment thesis for Replimune Group, Inc. It is a standard practice for executive retention and alignment, not indicative of new operational performance or strategic shifts that would warrant a change in investment recommendation.

Keywords

Replimune Group, REPL, Restricted Stock Units, RSU grant, insider transaction, executive compensation, Form 4, Konstantinos Xynos, Chief Medical Officer